Avera Gettysburg v. Teva Pharmaceutical Industries, Ltd.

CourtDistrict Court, D. Minnesota
DecidedMay 7, 2024
Docket0:23-cv-03882
StatusUnknown

This text of Avera Gettysburg v. Teva Pharmaceutical Industries, Ltd. (Avera Gettysburg v. Teva Pharmaceutical Industries, Ltd.) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Avera Gettysburg v. Teva Pharmaceutical Industries, Ltd., (mnd 2024).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA

Avera Gettysburg, doing business as No. 23-cv-3882 (KMM/LIB) Avera Gettysburg Hospital, et al.,

Plaintiffs,

v. ORDER

Teva Pharmaceutical Industries, Ltd., et al.,

Defendants.

This matter is before the Court on Plaintiffs’ Motion to Remand pursuant to 28 U.S.C. § 1447(c). Pls.’ Mot. (Doc. 11). Plaintiffs argue that this case should be remanded to state court due to lack of subject matter jurisdiction. Defendants oppose the motion. Defs.’ Opp’n (Doc. 17). Because the Court agrees that subject matter jurisdiction is absent, the Plaintiffs’ motion is granted and this matter is remanded to Hennepin County District Court. BACKGROUND Plaintiffs, which include several hospitals and healthcare systems, filed this case in the Fourth Judicial District, Hennepin County District Court, on November 14, 2023. Compl. (Doc. 1-1). Plaintiffs name several companies that market and distribute opioid medications as Defendants, dividing them into groups of “Marketing Defendants” and “Distributor Defendants.” Generally, Plaintiffs allege that the Marketing Defendants have engaged in false, deceptive, and unfair marketing of opioids, and that all Defendants breached duties to protect against suspicious opioids, all of which created a public health epidemic. Further, they allege that the Distributor Defendants unlawfully distributed opioids by failing to detect, block and report suspicious orders and misrepresented their

compliance with legal duties. The Complaint includes ten claims for relief. The first six claims are asserted under the statutes of Minnesota, Nebraska, North Dakota, and South Dakota, which impose protections against consumer fraud, deceptive trade practices, and false advertising.1 The remaining four claims are common law torts, including nuisance (Seventh Claim for

Relief), fraud and deceit (Eighth), civil conspiracy (Ninth), and unjust enrichment (Tenth). On December 22, 2023, Defendant Cardinal Health, Inc. filed a Notice of Removal in this Court asserting that Plaintiffs’ claims “arise under federal law.” Notice of Removal ¶ 1 (Doc. 1). According to Cardinal Health, Plaintiffs alleged that it and “other Defendants violated and are liable under a federal statute, the Controlled Substances Act, 21 U.S.C.

§ 801, et seq. (the “CSA”) and its implementing regulations.” Id. Accordingly, Cardinal Health asserted that this action is removable because it necessarily raises a federal claim for purposes of determining jurisdiction under 28 U.S.C. § 1331. Id. ¶¶ 13–37. Plaintiffs filed their motion to remand on January 18, 2024, arguing that the case must be remanded

1 The First Claim for Relief references Minnesota’s Prevention of Consumer Fraud Act, Minn. Stat. § 325F.68, et seq. The Second Claim for Relief asserts violations of Minnesota’s Deceptive and Unfair Trade Practices Act, Minn. Stat. §§ 325D.43 through 326D.48. The Third Claim for Relief alleges violations of Nebraska’s Consumer Protection Act, Neb. Rev. Stat. §§ 59- 1601, et seq. The Fourth Claim for Relief points to North Dakota’s Consumer Fraud Act, N.D.C.C. § 51-15-01, et seq. The Fifth Claim for Relief alleges violations of South Dakota’s Deceptive Trade Practices and Consumer Protection Act, SDCL § 37-24-21, et seq. And the Sixth Claim for Relief is brought under Minn. Stat. § 325F.67, which addresses false statements in advertising. to Hennepin County District Court because it raises exclusively state law claims, none of those claims present a substantial federal question, and Defendants’ position to the contrary has been repeatedly rejected by other courts. Pls.’ Mem. (Doc. 14).

DISCUSSION I. Legal Standard A plaintiff may bring a motion to remand a case removed to federal court challenging the court’s jurisdiction over the suit, and if “it appears that the district court lacks subject matter jurisdiction, the case shall be remanded.” 28 U.S.C. § 1447(c).

“Critically, the party seeking removal has the burden to establish federal subject matter jurisdiction, [and] all doubts about federal jurisdiction must be resolved in favor of remand[.]” Central Power Co-op. v. Midwest Indep. Transmission Sys. Operator, Inc., 561 F.3d 904, 912 (8th Cir. 2009) (citations omitted). A defendant may remove an action from state court to federal district court where

“at least one claim falls within the original jurisdiction of the federal court.” Minnesota v. Am. Petrol. Inst., 63 F.4th 703, 709 (8th Cir. 2023). One source of original jurisdiction is 28 U.S.C. § 1331, which provides that “district courts shall have original jurisdiction of all civil actions arising under the Constitution, laws, or treaties of the United States.” Federal district courts have such “federal question jurisdiction” only when the plaintiff’s complaint

presents the federal question on its face. Am. Petrol. Inst., 63 F.4th at 709. Under the well- pleaded complaint rule, a plaintiff “‘may avoid federal jurisdiction by exclusive reliance on state law.’” Id. (quoting Caterpillar Inc. v. Williams, 483 U.S. 386, 392 (1987)). Two exceptions to the well-pleaded complaint rule can support removal even where the face of the complaint presents no federal question. Cagle v. NHC Healthcare-Maryland Heights, LLC, 78 F.4th 1061, 1066 (8th Cir. 2023). These exceptions apply “when the state

law claims (1) are completely preempted by federal law or (2) necessarily raise a substantial, disputed federal question.” Id. (quotations omitted). This case involves the second of these exceptions.2 The second exception to the well-pleaded complaint rule, which is sometimes referred to as the “Grable doctrine,”3 Am. Petrol. Inst., 63 F.4th at 711, applies in a

“‘special and small category of cases,’” Cagle, 78 F.4th at 1067 (quoting Gunn v. Minton, 568 U.S. 251, 258 (2013). Under this doctrine “federal jurisdiction over a state law claim will lie if a federal issue is (1) necessarily raised, (2) actually disputed, (3) substantial, and (4) capable of resolution in federal court without disrupting the federal-state balance approved by Congress.” Id. (citing Gunn, 568 U.S. at 258).

A state law claim ‘necessarily raises’ a federal issue when the question of federal law is a ‘necessary element of one of the well-pleaded state claims.” Id. (quoting Franchise Tax Bd. v. Constr. Laborers Vacation Tr., 463 U.S. 1, 13 (1983)). But the issue of “necessity” must be assessed with “precision.” Am. Petrol. Inst., 63 F.4th at 711 (quoting Cent. Iowa Power Coop. v. Midwest Indep. Transmission Sys. Oper., Inc., 561 F.3d 904,

914 (8th Cir. 2009)). “A removing defendant should be able to point to the specific

2 Defendants do not argue that Plaintiffs’ claims are completely preempted by federal law. Defs.’ Opp’n, passim. 3 Grable & Sons Metal Prods., Inc. v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gunn v. Minton
133 S. Ct. 1059 (Supreme Court, 2013)
Anderson v. State, Department of Natural Resources
693 N.W.2d 181 (Supreme Court of Minnesota, 2005)
North Star Legal Foundation v. Honeywell Project
355 N.W.2d 186 (Court of Appeals of Minnesota, 1984)
Hill v. Stokely-Van Camp, Inc.
109 N.W.2d 749 (Supreme Court of Minnesota, 1961)
Williamson v. Kelley
271 N.W.2d 727 (Supreme Court of Iowa, 1978)
David Zink v. George Lombardi
783 F.3d 1089 (Eighth Circuit, 2015)
Zane Cagle v. NHC Healthcare
78 F.4th 1061 (Eighth Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
Avera Gettysburg v. Teva Pharmaceutical Industries, Ltd., Counsel Stack Legal Research, https://law.counselstack.com/opinion/avera-gettysburg-v-teva-pharmaceutical-industries-ltd-mnd-2024.